Pharmaceutics · 2022 · 11 citations · 18 references
MedicineOncologyPharmacologyApoptosisChemotherapyImmunotherapyCancer ImmunotherapyCancer NanomedicineImmune Checkpoint InhibitorsNanomedicineTargeted Cancer TherapyTargeted TherapyCancer Cell ApoptosisCancer NanotherapyCombination TherapyPd-l1 BlockadeProgrammed Cell Death Ligand 1 InhibitionProgrammed Death-ligand 1 InhibitionProgrammed Death-ligand 1 InhibitorsProgrammed Death-ligand 1 Targeting
PD-1 inhibitor Keytruda combined with chemotherapy for Triple-negative breast cancer (TNBC) has been approved for FDA, successfully representing the combination therapy of immunotherapy and chemotherapy for the first time in 2020. However, PD-L1 inhibitor Tecentriq combined with albumin paclitaxel using the similar strategy failed to achieve the expected effect. Therefore, it is still necessary to explore new effective immunotherapy and chemotherapy-based combined strategies. We developed a cell membrane-derived programmed death-ligand 1(PD-1) nanovesicle to encapsulate low-dose gemcitabine (PD-1&GEM NVs) to study the effect on breast cancer in vitro and in vivo. We found that engineered PD-1&GEM NVs could synergistically inhibit the proliferation of triple-negative breast cancer, which interacted with PD-L1 in triple-negative breast cancer to disrupt the PD-L1/PD-1 immune inhibitory axis and promoted cancer cell apoptosis. Moreover, PD-1&GEM NVs had better tumor targeting ability for PD-L1 highly-expressed TNBC cells, contributing to increasing the drug effectiveness and reducing toxicity. Importantly, gemcitabine-encapsulated PD-1 NVs exerted stronger effects on promoting apoptosis of tumor cells, increasing infiltrated CD8+ T cell activation, delaying the tumor growth and prolonging the survival of tumor-bearing mice than PD-1 NVs or gemcitabine alone. Thus, our study highlighted the power of combined low-dose gemcitabine and PD-1 in the nanovesicles as treatment to treat triple-negative breast cancer.
18
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine · 2018 · 4.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.8K citations · Full text
Medicine, Oncology, Pharmacology +16
David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text
Medicine, Oncology, Pharmacology +17